A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)

Inclusion Criteria: * Parent or legal guardian is able to provide written informed consent and patient is able to provide written assent if appropriate. * Male and female adolescents aged 12 to 16 years at the time of enrollment. * Diagnosed with JIA, including all the International League of Associations for Rheumatology JIA subtypes: oligoarthritis, polyarthritis (both rheumatoid factor \[RF\]+ and RF-), psoriatic arthritis, enthesitis-related arthritis, undifferentiated arthritis, and systemic arthritis. * Based upon investigator judgment, it is determined appropriate for the patient to undergo 6 months of continuous treatment with VIMOVO. * Body weight \> 31 kg (68.2 lbs) and within the 5th to 95th percentile of body mass index for age. Exclusion Criteria: * In systemic JIA patients, presence of systemic features (ie, fever, rheumatoid rash, serositis, lymphadenopathy, macrophage activation syndrome) within 6 months prior to start of study drug. * Currently taking (ie, within 4 weeks prior to start of drug) naproxen \> 20 mg/kg/day or \> 1000 mg total daily dose. * Hemoglobin ≤ 8.5 g/dL. * Individuals who have cardiovascular or cerebrovascular disease, based on history or risk factors. * Any significant hepatic, renal, pulmonary, ophthalmologic, neurologic, or any other medical conditions indicated by medical/surgical history, physical, or laboratory examination that might put the patient at greater risk during the study.